Skip to main navigation
  • About Us
    • Our Core Values
    • Senior Management
    • Board of Directors
    • Collaborations
  • Products
    • MARGENZA®
  • Pipeline
    • MGC018 (B7-H3)
    • Enoblituzumab (anti-B7-H3)
    • Lorigerlimab (PD-1 x CTLA-4)
    • Tebotelimab (PD-1 x LAG-3)
    • IMGC936 (ADAM9)
    • Retifanlimab (PD-1)
    • MGD014 (HIV × CD3)
  • Platforms
    • DART® and TRIDENT®
    • Fc Optimization
  • Patients
    • Clinical Trials
    • Expanded Access
  • Investors

    Investor Relations

    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Senior Management
      • Board of Directors
      • Committee Composition
      • Contact the Board
    • Financials & Filings
      • SEC Filings
      • Quarterly Results
      • Key Metrics
    • Stock Information
      • Historic Stock Lookup
      • Investment Calculator
      • Analyst Coverage
      • Ownership Profile
    • Investor FAQs
    • Publications
    • Contact Us
  • Careers at Macrogenics
    • Current Openings
    • Employee Benefits

Event Details

Shareholder Tools


  • Facebook
  • LinkedIn
  • Twitter
  • RSS

Breadcrumb

Home Investors events event details 63rd ASH Annual Meeting & Exposition

63rd ASH Annual Meeting & Exposition

Dec 11 - Dec 13, 2021

Supporting Materials

Combinatorial Anti-Tumor Activity in Animal Models of a Novel CD123 x CD3 Bispecific DART® Molecule (MGD024) with Cytarabine, Venetoclax or Azacitidine Supports Combination Therapy in Acute Myeloid Leukemia 1.8 MB
    • About Us
    • Our Living Values
    • Senior Management
    • Board of Directors
    • Collaborations
    • Products
    • MARGENZA™
    • Pipeline
    • MGC018 (B7-H3)
    • Enoblituzumab (anti-B7-H3)
    • Lorigerlimab (PD-1 × CTLA-4)
    • Tebotelimab (PD-1 × LAG-3)
    • IMGC936 (ADAM9)
    • Retifanlimab (PD-1)
    • MGD014 (HIV × CD3)
    • Platforms
    • DART® and TRIDENT®
    • Fc Optimization
    • Patients
    • Clinical Trials
    • Expanded Access
    • Investors
    • Footer investor menu

      • Press Releases
      • Events & Presentations
      • Corporate Governance
      • Financials & Filings
      • Stock Information
      • Investor FAQs
      • Publications
      • Contact Us
    • Careers
    • Current Openings
    • Employee Benefits
©2022 MacroGenics, Inc.
  • Contact Us
  • Site Map
  • Privacy Policy
  • Terms of Use
  • Other Notices